Dr. Arifa S. Khan is Head, Molecular Retrovirology Unit, Division of Viral Products, Office of Vaccines Research and Review, in the Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. Her current research efforts are focused on establishment and implementation of high-throughput sequencing technologies for adventitious virus and endogenous retrovirus detection for safety evaluation of cell substrates and biological products. Dr. Khan's primary regulatory responsibilities include review submissions related to viral vaccines, including HIV-1, influenza virus, RSV and SARS-COV-2. She also provides expert consultation on viral safety testing to OTAT/CBER and CDER offices. Dr. Khan has been involved in licensure of several viral vaccines and has contributed to the development of FDA, ICH, EDQM, PHS, USP, and WHO documents. Most recently, she served as the FDA Deputy Topic Lead in the Expert Working Group for updating the ICH Q5A(R2) guideline on viral safety of biotechnology products and contributed to the development of the Ph. Eur. 2.6.41 chapter on High Throughput Sequencing. Dr. Khan obtained her Ph.D. in Microbiology from George Washington University, Washington, D.C. She has authored more than 100 publications.